This invention is a buccal drug delivery platform which topically targets oral cancer cells in the mouth for improved treatment of oral cancer.
While the prevalence of many cancers is decreasing, the incidence of oral cancer (OC) has been increasing with over 640,000 cases diagnosed annually. Despite the fact that OC treatment is incredibly expensive with an annual cost of care of ~$80,000 per patient for medical, pharmacy, and dental care, an amount which doubles when surgery, radiation, and chemotherapy are combined, OC has only a 50% five year survival rate. This technology treats OC by replacing intravenous (IV) delivery with topical and buccal delivery, significantly reducing the overall cost of OC treatment, by more effectively delivering cisplatin (CIS) to oral cancer cells and reducing toxicity in healthy tissue.
This invention is a safe and effective nanoparticle (NP) drug delivery system for the local treatment of non-metastatic OC, which accounts for 90% of OC. The controlled release NP design will dispense a steady amount of the drug that targets the cancer tissues while minimizing toxic side effects to the surrounding healthy tissues and comprises of the active drug compound CIS, the NP polymer chitosan (CHI), chemical linker poly(ethylene glycol) (PEG), and the targeting moiety arginylglycylaspartic acid (RGD). The NPs will be delivered via a bilayer sponge placed directly on the tumor with NPs in one layer and a plasticized, non-porous, non-permeable layer that forces a unidirectional NP release. PEG and CHI increase drug permeability while RGD peptide provides active targeting. The nano encapsulation of CIS offers a number of benefits including increased protection from CIS on healthy cells, high drug loading, controlled release, improved permeability, increased bioadhesivity, and masking of CIS’s metallic taste. Furthermore, patients may administer CIS in their own homes, avoiding the inconvenience and expense of chemotherapy clinics encouraging early treatment to significantly raise survival rate.
- Less toxic, easy to dose, and convenient, allowing patients to self-administer early treatment at home
and effective controlled release for local treatment
to cancer cells minimizes toxic side effects
- No undesirable
metallic taste of platinum